Short report

Leucodystrophy and oculocutaneous albinism in a child with an 11q14 deletion

Isabelle Coupry, Laurence Taine, Cyril Goizet, Carine Soriano, Bruno Mortemousque, Benoît Arveiler, Didier Lacombe

Laboratoire de
Pathologie Moléculaire
et Thérapie Génique,
Université Victor
Segalen Bordeaux 2,
146 Rue Léo Saignat,
33076 Bordeaux Cedex,
France

I Coupry
L Taine
C Goizet
C Soriano
B Arveiler
D Lacombe

Service de Génétique
Médicale, CHU
Bordeaux, France

L Taine
C Goizet
B Arveiler
D Lacombe

Service
d'Ophthalmologie,
CHU Bordeaux,
France
B Mortemousque

Correspondence to:
Dr Coupry,
Isabelle.coupry@
pmtg.u-bordeaux2.fr

Revised version received
20 July 2000
Accepted for publication
15 August 2000

Abstract

We report a patient with an undetermined leucodystrophy associated with type 1A oculocutaneous albinism (OCA). Type 1 OCA results from recessive mutations in the tyrosinase gene (*TYR*) located in 11q14.3. The patient was found by FISH to carry a deletion of at least the first exon of the *TYR* gene on one chromosome and a (TG) deletion at codon 244/245 on the second chromosome. The existence of the microdeletion suggested that a gene responsible for leucodystrophy was located in the vicinity of the *TYR* gene. A combination of a test of hemizygosity and contig mapping studies allowed us to map the gene within a 0.6 cM region flanked by microsatellite markers D11S1780 and D11S931.

(J Med Genet 2001;38:35–39)

Keywords: leucodystrophy; oculocutaneous albinism; 11q14 deletion; physical mapping

The leucodystrophies are a heterogeneous group of rare hereditary diseases affecting the central nervous system (CNS). They display a hereditodegenerative process mostly affecting the white matter and leading to diffuse demyelination of the CNS. Clinical evidence of the diagnosis may be confirmed by brain imaging (magnetic resonance imaging rather than CT scanning), which shows characteristic signal abnormalities in the white matter. The cause of 36% of all leucodystrophies is

unknown since no specific biochemical or genetic abnormality can be identified, thus rendering the classification of patients into homogeneous subgroups impossible.¹ The diagnosis is therefore made by eliminating all known abnormalities identified so far, such as raised blood levels of very long chain fatty acids in adrenoleucodystrophy, lysosomal enzyme deficiency in urine and blood in Krabbe's disease, metachromatic leucodystrophy, and Canavan's disease, or proteolipoprotein mutation in Pelizaeus-Merzbacher disease.² A useful approach towards identifying the genes involved in these disorders is to search for chromosomal rearrangements in patients. We report a patient with an undetermined leucodystrophy associated with type 1A oculocutaneous albinism (OCA). Type 1A OCA results from deficient catalytic activity of tyrosinase, the gene for which (*TYR*) is located in 11q14.3.³ This gene was found by FISH to be deleted in the patient. The existence of the microdeletion suggested that the gene responsible for leucodystrophy in this patient was located in the vicinity of the *TYR* gene. The work presented here allowed us to map the gene within a 0.6 cM region framed by microsatellite markers D11S1780 and D11S931.

Case report

The patient is the third and last son of non-consanguineous French parents. The family history is uninformative. The patient was born at 38 weeks' of gestation after an uneventful pregnancy and delivery (birth weight 3040 g). OCA was noted at birth since there was total depigmentation of the skin, hair, and iris associated with nystagmus. The patient walked at 19 months. Speech was retarded. A visual deficit was noted in early childhood, so he was cared for in an institution for the visually deficient. Mental retardation became manifest later in childhood. At the age of 15 years, generalised epileptic episodes occurred, requiring antiepileptic treatment. An electroencephalogram was abnormal and cranial magnetic resonance imaging (MRI) showed diffuse signals of increased intensity in the white matter on T2 images typical of leucodystrophy (fig 1). At the age of 18, mental retardation was moderate (IQ=51). Examination showed diffuse hyperreflexia, slight dysmorphism including bulbous nose and prognathism, and gynaecomastia in addition to

Figure 1 Cranial MRI images of the patient. Note the almost symmetrical hyperintense T2 changes throughout the periventricular regions, predominantly around the posterior horns of the lateral ventricles.

Figure 2 Patient's front view. Note the total depigmentation of the hair, eyebrows, and eyelashes as well as the slight dysmorphism with bulbous nose and prognathism.

the above mentioned signs (fig 2). There was no sign of peripheral demyelination on electromyography, which displayed normal signals. P100 wave was absent on the left and very altered on the right on visual evoked potentials while somatosensory and auditory evoked potentials were normal. No abnormalities were found in standard laboratory investigations, blood amino acids on chromatography, VLCFA, phytanic acid, pipecolic acid, pristanic acid, or leucocytic lysosomal enzymes, classifying the leucodystrophy as undetermined. OCA was classified as type 1 after a search for tyrosinase activity in hair roots proved negative.

Material and methods

Informed consent was obtained from the patient before inclusion in the study.

KARYOTYPING AND FLUORESCENCE IN SITU HYBRIDISATION

Chromosome preparations were made from peripheral blood cultures by conventional methods from the patient and his parents. High resolution R banding was obtained by introduction of 5-bromodeoxyuridine (BrdU) for 5.5 hours in cell cultures, after thymidine synchronisation.⁴

A human tyrosinase recombinant λ phage, λ hTyr34,⁵ containing the first *TYR* exon was labelled with digoxigenin-11-dUTP using the Dig-Nick-translation kit from Boehringer Mannheim Inc. One hundred ng of the labelled DNA was preannealed with 2.5 μ g *CoI* DNA (Gibco BRL) in a total volume of 10 μ l hybridisation mix (50% formamide, 2 $\times$ SSC, 10% dextran sulphate) containing 0.5 μ l chromosome 11 alpha satellite biotinylated probe (Oncor Appligene) for 30 minutes at 37°C. Hybridisation to denatured chromosomes was done overnight at 37°C. Post hybridisation wash was carried out at 72°C in 2 $\times$ SSC for five minutes. Probe detection was performed with a FITC conjugated mouse antidigoxin antibody (Sigma) and cyanin 3 conjugated extravidin (Cy3, Sigma). Using the fluorescence plus Giemsa modified method⁶ resulted in a high resolution R banding pattern. After UV exposure, a second round of signal amplification was performed with additional layers of a rabbit antimouse FITC conjugated antibody (Sigma) to amplify the *TYR* signal and a biotinylated goat antiavidin antibody (Vector Laboratories), shown by cyanin 3 conjugated extravidin, to amplify the chromosome 11 alpha satellite signal. Slides were mounted in antifade solution (Vectashield, Vector Laboratories) containing 4',6-diamidino-2-phenyl indole (DAPI) as a counterstain. Slides were analysed on a Zeiss Axioskop microscope equipped with a Pinkel filter set for visualisation of FITC, Cy3, and DAPI fluorescence. Digital images were recorded with a Photometrics cooled CCD camera. Pseudocolouring and merging of images were performed with the Mac Probe 3.3 software (PSI, League City, Texas).

PCR AMPLIFICATION AND SEQUENCING OF THE TYROSINASE GENE

Primers P1 to P12 (Oligo Express, France), used to amplify the tyrosinase exons, have been

previously described.^{3,5} The PCR procedures involved a first step of 10 minutes at 95°C to activate the AmpliTaq Gold DNA polymerase (Perkin Elmer), which was followed by 35 cycles of heat denaturation for 30 seconds at 94°C, annealing for 30 seconds at various temperatures (exon 1, 50°C, 1 mmol/l MgCl₂; exons 2, 3, 4, 50°C, 1.5 mmol/l MgCl₂; and exon 5, 55°C, 2.5 mmol/l MgCl₂), and extension at 72°C for one minute. The reaction ended with a five minute extension step at 72°C. The reaction buffer contained 1 mmol/l of each oligonucleotides, 0.2 mmol/l dNTPs, and 1 U of AmpliTaq Gold, in a 25 μ l reaction. Amplification was carried out using an Omni-gene Thermal Cycler (Hybaid).

PCR products were purified with the QIAquick PCR purification kit (QIAGEN) according to the manufacturer's instructions and were sequenced using the dRhodamine Terminator Cycle Sequencing Ready Reaction kit (Perkin-Elmer), on an ABI377 automatic sequencer (Applied Biosystems). The DNA sequencing reactions were performed with the primers used for amplification, except for exon 1 for which two additional internal primers (1PA and 1PB) were used.³

TEST FOR HEMIZYGOSITY

The test for hemizyosity was performed with eight polymorphic microsatellite markers mapped in the vicinity of the *TYR* locus, according to the Marshfield Map (<http://www.marshmed.org/genetics/>). Genomic DNA from the patient and his parents was amplified with 6-FAM labelled primers corresponding to microsatellites D11S931, D11S1342, D11S1354, D11S1358, D11S1367, D11S1780, D11S1887, and D11S4082. PCR parameters and cycling conditions were optimised for each marker and are available from the authors on request. Fragment length analysis was performed on an ABI377 automatic sequencer (Applied Biosystems) using the GeneScan software.

Results and discussion

KARYOTYPING AND FLUORESCENCE IN SITU HYBRIDISATION

High resolution prometaphase karyotypes were normal for the patient and his parents. High resolution prometaphase chromosomes were hybridised with both a chromosome 11 alpha satellite probe and the λ hTyr34 probe that contains the 5' region of the *TYR* gene, including exon 1.⁵ The results obtained showed that *TYR* maps to band 11q14.3 (data not shown), thus refining previous mapping data reported by others in lower resolution FISH experiments^{7,8} and confirming our contig mapping data.³ FISH analysis of the patient's chromosomes showed the existence of a de novo microdeletion in 11q14.3 (fig 3). The patient's parents did not carry the microdeletion (data not shown).

IDENTIFICATION OF THE SECOND *TYR* MUTATION RESPONSIBLE FOR OCULOCUTANEOUS ALBINISM

Since OCA1A is an autosomal recessive trait, the second causative mutation was searched for by direct sequencing of the five *TYR* exons. A

Figure 3 FISH analysis of the patient's peripheral blood lymphocytes. The digoxigenylated phage λ hTyr34 and the biotinylated chromosome 11 alpha satellite probes were detected with a FITC conjugated antidigoxin antibody and Cy3 conjugated extravidin, respectively. Metaphase showing only the chromosome 11 alpha satellite signal (arrow) and both λ hTyr34 and chromosome 11 alpha satellite signals on the normal chromosome 11 (arrowhead).

two base pair (TG) deletion in codons 244/5 of the first *TYR* exon was found (fig 4), which produces a shift in the reading frame leading to a stop codon. This mutation was already described in a patient with OCA1A.⁹ The mutation was inherited from the father, implying that the 11q14.3-q21 deletion had therefore occurred on the maternal chromosome.

REFINED MAPPING OF THE DELETION BREAKPOINT REGION

In order to evaluate the extent of the deletion, a test for hemizyosity was performed using eight microsatellite markers located in the 11q14.3 region. The order of the markers on the Marshfield integrated map was: cen - D11S1354 - D11S4082 - D11S1887 - D11S1780 - D11S931 - D11S1367 - D11S1342 - D11S1358 - tel. Owing to uncertainties about marker order in other databases, a PCR based STS analysis of these markers was performed on a previously constructed YAC contig encompassing about 2 Mb of the region of interest, on which *TYR*, D11S931, D11S1342, and D11S1358 were already mapped.³ Data presented in fig 5 indicate that D11S1367 maps immediately proximal to *TYR*, probably within 100 kb of the 5' end of the gene as estimated on the basis of the YAC insert sizes. This result is at variance with the Marshfield map order. The absence of markers D11S1354, D11S4082, D11S1887, and D11S1780 on the YACs indicates that these markers are centromeric to D11S1367 and are distant from this marker by at least 300 kb. Altogether, our data suggest that the order of markers is cen - D11S1354 - D11S4082 - D11S1887 - D11S1780 - D11S1367 - *TYR* - D11S931 - D11S1342 - D11S1358 - tel.

A test of hemizyosity was performed using this map as a framework. Results presented in table 1 show that D11S1367 was deleted in the patient, whereas D11S1887, D11S1780,

Figure 4 Sequence analysis of the *TYR* gene exon 1. Alignment of sequences for the patient (lane 4) and his parents (lane 2 father, lane 3 mother) compared to the *TYR* exon 1 reference sequence (lane 1) is shown. The sequencing reaction was performed using primer P1B.² The arrows indicate the deletion observed in the patient and his father.

Figure 5 YAC contig map of the 11q14.3 region. Markers tested are represented in the upper part of the figure. The presence of a marker in a YAC is indicated by a vertical bar. YAC sizes in kb are indicated in parentheses.

D11S931, D11S1342, and D11S1358 were not. The absence of a maternal allele at D11S1367 confirmed that the deletion had occurred on the maternal chromosome, as already indirectly indicated by the inheritance of the *TYR* exon 1 (TG) deletion at codon 244/245 from the father.

In summary, our data indicate that the deletion found in the patient is framed by markers D11S1780 on the proximal side and by D11S931 on the distal side, a region estimated at about 0.6 cM on the Marshfield map.

Conclusion

We describe a patient with a de novo 11q14.3 microdeletion presenting with both oculocutaneous albinism type 1 and leucodystrophy. The deletion was characterised at the molecular level both by FISH using a *TYR* probe containing the first exon of the gene and by showing hemizyosity at D11S1367. According to our physical mapping data, we estimate that *TYR* and D11S1367 are separated by about 100 kb. The closest non-deleted markers found in the patient are D11S1780 and D11S931 (0.6 cM). Our data therefore suggest that a new gene responsible for leucodystrophy is present in 11q14.3. According to our contig mapping data (fig 5), the size of the deletion interval is larger than 1.4 Mb (distance between D11S931 and the end of the 12GE1 YAC). The extent of the deletion needs further characterisation in order to search for candidate genes and identify the gene responsible for leucodystrophy in this patient. More than 40 ESTs and genes are located in the critical region but their exact position on the map, especially their presence

or absence in the deleted region, remains unknown. Attention will be particularly given to the genes and ESTs that are expressed in the brain, such as embryonic ectoderm development protein (*EED*), mitochondrial NADP(+) dependent malic enzyme 3 (*ME3*), and chapsyn-110 (*DLG2*). The cathepsin C gene, which encodes a lysosomal protease expressed in the brain, is another candidate, since most leucodystrophies of known cause are lysosomal diseases.³ Although the cathepsin C gene was recently identified as responsible for Papillon-Lefèvre syndrome,¹⁰ its potential role in the leucodystrophy of our patient will also be investigated.

The first two authors contributed equally to this work. We thank Fabienne Ballanger and Virginie Dupart for their technical contribution to this work. This work was supported by grants from Institut National de la Santé Et de la Recherche Médicale (CRI 9504), Association Française pour la Recherche en Génétique (AFRG), European Leukodystrophy Association (ELA), and Association pour la Recherche Médicale en Aquitaine (ARMA).

Table 1 Test for hemizyosity using microsatellite markers from the 11q14 region

Microsatellite markers	Allele size (bp)			Comment*
	Father	Mother	Patient	
D11S1354	169/179	179/179	179/179	NI
D11S4082	123/127	123/125	123/123	NI
D11S1887	267/275	261/261	267/261	ND
D11S1780	183/191	173/189	191/189	ND
D11S1367	227/231	227/233	231/—	D
D11S931	266/266	261/266	266/261	ND
D11S1342	261/265	263/263	261/263	ND
D11S1358	144/146	137/144	137/144	ND

Allele sizes are indicated in bp for each marker.

*ND: not deleted, NI: not informative, D: deleted.

- Kristjansdottir R, Uvebrant P, Hagberg B, Kyllerman M, Wiklund LM, Blennow G, Flodmark O, Gustavsson L, Ekholm S, Mansson JE. Disorders of the cerebral white matter in children. The spectrum of lesions. *Neuropediatrics* 1996;27:295-8.
- Baraitser M. Metabolic disorders/degenerative diseases of childhood. In: *The genetics of neurological disorders*. 3rd ed. Oxford: Oxford Medical Publication, 1997:283-333.
- Petit J, Boisseau P, Taine L, Gauthier B, Arveiler B. A YAC contig encompassing the 11q14.3 breakpoint of a translocation associated with schizophrenia, and including the tyrosinase gene. *Mam Genome* 1999;10:649-52.
- Viégas-Péquignot E, Dutrillaux B. Une méthode simple pour obtenir des prophases et des prométaphases. *Ann Genet* 1978;25:122-4.
- Giebel LB, Strunk KM, Spritz RA. Organization and nucleotide sequences of the human tyrosinase gene and a truncated tyrosinase-related segment. *Genomics* 1991;9:435-45.
- Cherif D, Julier C, Delattre O, Derré J, Lathrop GM, Berger R. Simultaneous localisation of cosmid and chromosome R-banding by fluorescence microscopy: application to regional mapping of human chromosome 11. *Proc Natl Acad Sci USA* 1990;87:6639-43.
- Barton DE, Kwon BS, Francke U. Human tyrosinase gene, mapped to chromosome 11 (q14-q21), defines second region of homology with mouse chromosome 7. *Genomics* 1988;3:17-24.
- Evans KL, Fantes J, Simpson C, Arveiler B, Muir W, Fletcher J, van Heyningen V, Steel KP, Brown SDM, St Clair D, Porteous DJ. Human olfactory marker protein maps close to tyrosinase and is a candidate gene for Usher syndrome type I. *Hum Mol Genet* 1992;2:115-18.
- Oetting WS, Mentink MM, Summers CG, Lewis RA, White JG, King RA. Three different frameshift mutations of the tyrosinase gene in type 1A oculocutaneous albinism. *Am J Hum Genet* 1991;49:199-206.
- Toomes C, James J, Wood AJ, Wu CL, McCormick D, Lench N, Hewitt C, Moynihan L, Roberts E, Woods CG, Markham A, Wong M, Widmer R, Ghaffar KA, Pemberton M, Hussein IR, Temtamy SA, Davies R, Read AP, Sloan P, Dixon MJ, Thakker NS. Loss-of-function mutations in the cathepsin C gene result in periodontal disease and palmo-plantar keratosis. *Nat Genet* 1999;23:421-4.